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AbstrACt
Introduction Assisted vaginal birth (AVB) can markedly 
improve maternal and neonatal outcomes arising from 
complications in the second stage of labour. Historically, 
both forceps and ventouse devices have been used to assist 
birth; however, they are not without risk and are associated 
with complications, such as cephalohaematoma, retinal 
haemorrhage and perineal trauma. As new devices are 
developed to overcome the limitations of existing techniques, 
it is necessary to establish their efficacy and effectiveness 
within randomised controlled trials (RCTs). A major challenge 
of evaluating complex interventions (ie, invasive procedures/
devices used to assist vaginal birth) is ensuring they are 
delivered as intended. It can be difficult to standardise 
intervention delivery and monitor fidelity, and account for 
the varying expertise of clinicians (accoucher expertise). This 
paper describes the protocol for a systematic review aiming to 
investigate the reporting of device standardisation, monitoring 
and training in trials evaluating complex interventions, using 
AVB as a case study.
Methods and analysis Relevant keywords and subject 
headings will be used to conduct a comprehensive search 
of MEDLINE, Embase, Cochrane Central Register of 
Controlled Trials, Cumulative Index of Nursing and Allied 
Health Literature and  ClinicalTrials. gov, for RCTs and pilot/
feasibility studies evaluating AVB. Abstracts will be screened 
and full-text articles of eligible studies reviewed for inclusion. 
Information relating to the following categories will be 
extracted: standardisation of device use (ie, descriptions of 
operative steps, including mandatory/flexible parameters), 
monitoring of intervention delivery (ie, intervention fidelity, 
confirming that an intervention is delivered as intended) and 
accoucher expertise (ie, entry criteria for participation, training 
programmes and previous experience with the device). Risk 
of bias of included studies will be assessed.
Ethics and dissemination Ethical approval is not required 
because primary data will not be collected. Findings will be 
disseminated by publishing in a peer-reviewed journal and 
presentations at relevant conferences.
IntroduCtIon
Assisted vaginal birth (AVB) is a vital proce-
dure that, in skilled hands, can markedly 
reduce maternal and neonatal complications 
in the second stage of labour.1 In the UK, 
approximately one in eight women require 
an AVB, which typically involves forceps and/
or ventouse devices.2 However, AVB is not 
without risk. A forceps-assisted birth confers 
an increased risk of perineal and vaginal 
trauma3 4 as well as faecal incontinence.4 5 
Ventouse-assisted births have a failure rate of 
approximately 30% as well as being associ-
ated with neonatal subgaleal haematoma and 
intracranial haemorrhage, leading to a statu-
tory warning in 2015 by the Food and Drug 
Administration.4 These problems, together 
with the threat of litigation, have contrib-
uted to a reduction in AVB rates worldwide. 
There has been a corresponding increase in 
Caesarean section rates, despite the fact that 
AVB often provides better outcomes at full 
dilation and prevents future problems, such 
as increased risk of abnormal placentation, 
scar rupture and unexplained stillbirth in 
subsequent pregnancies.6 7 Novel AVB devices 
may be able to address these known risks and 
strengths and limitations of this study
 ► This review will include all randomised controlled 
trials (RCTs)/feasibility studies evaluating assisted 
vaginal births (AVBs), regardless of the nature of the 
comparator, ensuring that all AVB data are captured.
 ► Specifically, the review will summarise reporting 
standards relating to standardisation and monitor-
ing of intervention delivery, and ways in which trials 
describe and account for clinician expertise in RCTs 
involving devices.
 ► The review is not limited to human studies, ensuring 
that any relevant AVB study is included.
 ► No language limitations have been set, ensuring that 
the review is as comprehensive and generalisable 
as possible.
 ► This review focuses only on RCTs and pilot/feasi-
bility studies, meaning that information from other 
study designs may be missed.
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attempt to transform the falling AVB rates worldwide. One 
example is the BD Odon Device. The device has an air 
cuff that, once placed around the baby’s head, is inflated. 
To assist the birth of the baby, the accoucher then applies 
traction on the sleeve, which is attached to the air cuff 
(figure 1). In contrast to the ventouse, which operates 
by exerting negative pressure on the baby’s head, the BD 
Odon Device exerts positive pressure via the air cuff. It is 
hypothesised that this may reduce neonatal intracranial 
bleeding, and that the circumferential positioning of the 
air cuff may reduce instrumental failure rates.
Despite the perceived benefits of novel devices, such 
as the BD Odon Device, novel devices are susceptible to 
‘optimism bias’. Optimism bias refers to the unjustified 
belief in ‘new or novel’ innovations.8 It is, therefore, neces-
sary for all pioneering technologies to undergo rigorous 
evaluation to ensure that the benefits and harms are fully 
investigated and establish whether they are better than 
the standard devices used in clinical practice. Many expert 
panels, including the European Clinical Research Infra-
structure Network, have suggested that more rigorous 
clinical evaluation of medical devices within randomised 
controlled trials (RCTs) is required.9–12 Currently, 
however, the pathway for evaluating novel procedures 
and devices is less distinct than that for pharmaceutical 
products, and specific barriers have been identified in 
undertaking RCTs in this area.13 A major challenge is 
that they are considered to be complex interventions—
defined as those with multiple interacting components 
that can act independently or interdependently to influ-
ence outcomes. This can create difficulties in establishing 
how the intervention should be delivered (standardisa-
tion) and ascertaining whether it is actually delivered as 
intended (intervention fidelity). An additional challenge 
is that the delivery of complex interventions can be influ-
enced by clinicians’ skill.
These issues have been acknowledged in reporting 
guidance documents, such as the CONSORT extension 
for non-pharmacological treatments (CONSORT-NPT).14 
CONSORT-NPT suggests that ‘precise details of the 
experimental treatment’, ‘details on whether and how 
the interventions were standardised’, ‘eligibility criteria 
for care providers’, ‘the number of care providers’, ‘a 
description of care providers expertise and qualification’ 
and ‘the number of patients treated by each care provider’ 
are reported.14 Additionally, ‘details of whether and how 
adherence of care providers to the protocol and of partic-
ipants to interventions was assessed’ is recommended.14 
Provision of this information is recommended to improve 
the quality of trial design and to enable successful inter-
ventions to be replicated in practice, improving the 
contextualisation of findings and reducing research waste. 
Currently, however, it is uncertain as to whether these 
reporting standards are met in RCTs involving complex 
interventions, such as devices. This study, therefore, aims 
to investigate the quality of reporting of intervention stan-
dardisation, monitoring and clinician expertise in trials 
involving devices, using AVB as a case study.
MEthods And AnAlysIs
The review will be conducted in line with the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses checklist.15
Eligibility criteria
Feasibility studies, pilot studies and RCTs will be included 
in the review if they meet the following inclusion criteria:
Participants
All females of any age having an AVB. Studies involving 
simulated patients or animals will also be included.
Intervention
AVB by forceps, vacuum extraction or a novel assisted 
birth device. All devices will be considered and will not be 
limited to a single type or manufacturer.
Comparator(s)
Comparator groups will include spontaneous vaginal 
birth, AVB using any device or Caesarean section. Pilot/
feasibility studies without a comparator group will also be 
included.
Figure 1 BD Odon Device components.
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Outcome(s)
Reporting standards relating to standardisation of device 
use, monitoring of whether the device was used as intended 
(intervention fidelity) and details of accoucher expertise 
will be extracted. Information about the ‘success’ and 
‘failure’ rates of the device, and adverse events, will also 
be collected.
search strategy and study selection
We will systematically search for RCTs involving AVB 
device(s) in MEDLINE, Embase, Cochrane Central 
Register of Controlled Trials, Cumulative Index of 
Nursing and Allied Health Literature and  ClinicalTrials. 
gov databases from inception to 30 November 2018. 
The computer-based searches will combine free text and 
subject headings (see online supplementary file).
Reference lists of included studies will be searched for 
additional relevant articles, including published proto-
cols. There will be no restrictions on language.
Identification and selection of papers
A customised inclusion/exclusion form will be used 
to screen abstracts and provide an audit trail. Titles 
and abstracts will be screened independently by two 
authors (EJH and NSB). Any conflicts will be resolved by 
discussion.
The full-text versions of papers retained after title and 
abstract screening will be screened for further assessment 
of their eligibility for inclusion.
data extraction and management
Data will be extracted independently by at least two asses-
sors for each paper (EJH, SR and NSB). A customised data 
extraction form will be used to collect relevant data from 
each paper. Data of interest will include general study 
details (author, year of publication and country of origin 
of study), details of study design (RCT, pilot or feasibility 
study), the number of participating centres and the total 
number of participants.
Standardisation of intervention delivery
Details of the device(s) and comparator(s) will be 
extracted. These will include verbatim descriptions 
relating to how the device should be delivered (including 
technical or operative steps) and how/whether this was 
standardised within the study. Details concerning the 
criteria for using the device, such as any mandatory, 
prohibited or flexible parameters, will be documented 
in accordance with an existing typology for considering 
standardisation of interventional procedures.16 Finally, 
assessors will record judgements about whether enough 
information is provided to be able to replicate device use 
in routine practice (yes/no/unsure).
Monitoring of whether the device was used as intended 
(intervention fidelity)
Any reporting of whether the device was used as intended 
(intervention fidelity) will be reported. Details of how 
intervention fidelity was measured will be documented 
(eg, within case report forms).
Accoucher expertise
The number of accouchers participating in the study, 
and delivering interventions in each trial group, will be 
recorded. If provided, the total number of births (and 
AVBs) in each study centre will be reported. Reporting 
of any information about accoucher expertise will be 
recorded including their grade, previous experience 
with the device(s) under investigation and any proto-
cols for supervision when using the device. Attempts to 
account for a potential learning curve in device delivery 
(eg, trial entry criteria for accouchers, such as a prespec-
ified number of deliveries) will be recorded, together 
with information about accoucher training (eg, manda-
tory courses, videos or other materials). Finally, accouch-
er-related outcomes, such as competence, confidence or 
knowledge, will be extracted.
Device success, failure and safety
Details of whether the device was used successfully will 
be recorded, together with information about ‘harms’ or 
‘adverse events’ in either women or their babies. Infor-
mation about causes or reasons for these events will be 
extracted verbatim.
Assessment of study quality
The Cochrane risk of bias tool will be used to evaluate 
bias in RCTs, and pilot or feasibility studies that involved 
randomisation.17 Non-randomised pilot and feasibility 
studies will be assessed by evaluating bias related to the 
process of trial recruitment, documentation of protocol 
non-adherence, reporting of a primary outcome, descrip-
tion of clear objectives and description of clear progres-
sion criteria.
data synthesis and statistical analysis
Data will be entered into a custom database. A narrative 
synthesis will summarise the findings. Any further data 
synthesis (such as meta-analyses) will depend on the 
number and quality of studies identified.
Patient and public involvement
Patients and the public were not involved in the design 
and development of this protocol.
EthICs And dIssEMInAtIon
The completed systematic review will be published in 
a peer-reviewed journal and presented at appropriate 
conferences. This protocol can further be adapted for 
the analysis of other devices within obstetrics and surgery.
This systematic review will provide important infor-
mation surrounding the quality of reporting in RCTs 
evaluating devices for AVB, relating to how device use is 
standardised in trials (standardisation), whether devices 
are used in trials as intended (monitoring/intervention 
fidelity) and what the level of accoucher training is. The 
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findings will inform the design of future pilot/feasi-
bility studies and/or RCTs in this area, by optimising the 
way that device use is standardised and monitored, and 
accoucher expertise is accounted for.
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